Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly
| Autor: | Susan M. Webb, B. Charbonnel, Christiane Ajzenberg, Brigitte Delemer, Werner A. Scherbaum, R Santen, F Jockenhoevel, Ph. Caron, L Foubert, H Prestele, Y. Bachelot, C. Cortet, Pedro J. Benito, Varela C, V Boerlin, Jean-Marc Kuhn, Patrick Roger, J Leclere, E. Torres, F Escobar-Jiménez, Sonia Gaztambide, J Bringer, L Perlemuter, Vincent Rohmer, Geneviève Sassolas, Y Lorcy, F Villamil, Philippe Chanson, Jochen Schopohl |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
medicine.medical_specialty
Chemotherapy business.industry Endocrinology Diabetes and Metabolism medicine.medical_treatment Octreotide acetate Octreotide Lanreotide medicine.disease law.invention chemistry.chemical_compound Endocrinology Somatostatin chemistry Randomized controlled trial law Internal medicine Acromegaly medicine business Intramuscular injection medicine.drug |
| Zdroj: | Clinical Endocrinology. 53:577-586 |
| ISSN: | 0300-0664 |
| DOI: | 10.1046/j.1365-2265.2000.01134.x |
| Popis: | BACKGROUND AND OBJECTIVE The most effective option for the medical treatment of patients with acromegaly is the use of somatostatin analogues. Long-acting depot formulations for intramuscular injection of two somatostatin analogues have recently become available: octreotide acetate LAR (Sandostatin® LAR®, Novartis Pharma AG) and lanreotide SR (Somatuline®, Ipsen Biotech). We wished to compare efficacy of octreotide LAR and lanreotide SR in acromegalic patients. PATIENTS AND METHODS A group of 125 patients with acromegaly (67 females; mean age, 47 years; 59 patients had previous pituitary irradiation) from 26 medical centres in France, Spain and Germany were studied. Before the study, all patients had been treated with intramuscular injections of lanreotide SR (mean duration, 26 months) at a dose of 30 mg which was injected every 10 days in 64 and every 14 days in 61 patients, respectively. All patients were switched from lanreotide SR to intramuscular injections of 20 mg of octreotide LAR once monthly for three months. In order to obtain efficacy and safety data of lanreotide SR under study conditions, it was decided to randomly assign at day 1, in a 3 : 1 ratio, the time point of the treatment switch; 27 of the patients were randomly assigned to continue the lanreotide SR treatment for the first 3 months of the study (group A); they were on octreotide LAR 20 mg from month 4–6. The other 98 patients were assigned to be switched to treatment with octreotide LAR 20 mg at day 1 (group B). In group B patients, octreotide LAR treatment was continued until month 6, with an adjustment of the dose based on GH levels obtained at month 3. RESULTS The mean GH concentration decreased from 9.6 ± 1.3 mU/l at the last evaluation on lanreotide SR to 6.8 ± 1.0 mU/l after three injections of octreotide LAR (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text